GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » EPS without NRI

InMed Pharmaceuticals (InMed Pharmaceuticals) EPS without NRI : $-0.84 (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals EPS without NRI?

InMed Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2024 was $-0.18. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.84.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 57.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 49.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for InMed Pharmaceuticals's EPS without NRI or its related term are showing as below:

INM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -181.4   Med: 6.9   Max: 74.7
Current: 57.8

During the past 13 years, InMed Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 74.70% per year. The lowest was -181.40% per year. And the median was 6.90% per year.

INM's 3-Year EPS without NRI Growth Rate is ranked better than
94.3% of 1298 companies
in the Biotechnology industry
Industry Median: 5.15 vs INM: 57.80

InMed Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.

InMed Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.85.


InMed Pharmaceuticals EPS without NRI Historical Data

The historical data trend for InMed Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals EPS without NRI Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.58 -43.14 -38.26 -0.98 -3.24

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 0.27 -0.75 -0.20 -0.18

Competitive Comparison of InMed Pharmaceuticals's EPS without NRI

For the Biotechnology subindustry, InMed Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's PE Ratio without NRI falls into.



InMed Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (NAS:INM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


InMed Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals (InMed Pharmaceuticals) Headlines

From GuruFocus

InMed Announces Appointment of Chief Operating Officer

By PurpleRose PurpleRose 07-18-2022